A must-see Industry CME symposium at the 43rd Annual Meeting of the
European Society for Blood and Marrow Transplantation (EBMT).

Register Now

Sunday, March 26, 2017


Registration
10:30 AM – 11:00 AM
CME Symposium / Q&A Session
11:00 AM – 12:30 PM


Palais des Congrès - Marseille Chanot
Les Goudes 1
Parc Chanot, Rond-Point du Prado
13009 Marseille, France


PROGRAM AGENDA
10:30 AM – 11:00 AM Registration
11:00 AM – 11:05 AM Welcome and Introductions
  Michael Boeckh, MD, PhD
11:05 AM – 11:25 AM Management Strategies for CMV in HSCT and Implications for GVHD
  Michael Boeckh, MD, PhD
11:25 AM – 11:45 AM CMV Cellular Immunotherapy and Vaccines
  Karl S. Peggs, MB, BCh, MA, MRCP, FRCPath
11:45 AM – 12:05 PM GVHD in HSCT: Emerging Therapies for Refractory Disease
  Sung Won Choi, MD, MS
12:05 PM – 12:20 PM Interactive Panel Discussion (Clinical Cases and Current Issues in CMV and GVHD in HSCT)
  All faculty
12:20 PM – 12:30 PM Audience Q&A and Discussion
  All faculty


FACULTY

Michael Boeckh, MD, PhD (Chair)
Member, Vaccine and Infectious Disease & Clinical Research Divisions
Head, Infectious Disease Sciences Program
Fred Hutchinson Cancer Research Center
Professor of Medicine, University of Washington
Seattle, Washington (USA)

Sung Won Choi, MD, MS
Associate Professor
Pediatric Hematology-Oncology
C.S. Mott Children’s Hospital
University of Michigan Health System
Ann Arbor, Michigan (USA)

Karl S. Peggs, MB, BCh, MA, MRCP, FRCPath
Professor of Transplant Science and Cancer Immunotherapy
UCL Cancer Institute
University College London Hospitals
London, England (UK)


TARGET AUDIENCE
This activity has been designed to meet the educational needs of clinicians who manage cytomegalovirus (CMV) infection and graft-vs-host disease (GVHD) in patients who undergo hematopoietic stem cell transplant (HSCT).


STATEMENT OF NEED
Cytomegalovirus (CMV) and graft-vs-host disease (GVHD) are important causes of morbidity and mortality in recipients of hematopoietic stem cell transplant (HSCT).

CMV infection occurs in up to 60% of HSCT patients and CMV disease occurs in 10% of HSCT patients in the preemptive therapy era.1,2 Considering the significant hematologic toxicity associated with many current antiviral agents, therapeutic advances are needed. New antiviral drugs, the use of virus-specific T cells to hasten immune reconstitution, and further dissection of the roles of innate and adoptive immunity will likely provide patient benefits and improve health outcomes in the coming years.3

Treatment refractory acute GVHD is associated with an adverse prognosis and current therapies often provide suboptimal outcomes.4 In addition to incomplete response, complications occur frequently and survival is often compromised. Resolution of inflammation and rapid immune reconstitution in steroid refractory acute GVHD remains an area of urgent clinical need.5 These factors highlight the importance of the development of novel therapies including small molecules, immunologic checkpoint regulators, cytokine suppressors and others to prevent and treat acute GVHD.5

1. Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Infect Ther. 2004;2:27-41.
2. Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol. 2000;16:25-40.
3. Boeckh M, Murphy WJ, Peggs KS. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant. 2015;21:S19-S24.
4. Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control. 2011;18(4):268-276.
5. Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood. 2014;124(3):363-373.


EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

  • Discuss important relationships between CMV and GVHD in HSCT
  • Summarize the management strategies for CMV in HSCT and implications for GVHD
  • Outline the mechanisms of CMV cellular immunotherapy and vaccines in immunocompromised HSCT recipients
  • Identify emerging therapies for refractory GVHD in HSCT recipients
  • Construct CMV and GVHD management strategies in HSCT to improve patient health outcomes

ACCREDITATION STATEMENT
The 'Postgraduate Institute for Medicine' (or) 'Optimizing Outcomes in CMV and GVHD in Stem Cell Transplant: A Focus on Leading Causes of Morbidity and Mortality' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 'Optimizing Outcomes in CMV and GVHD in Stem Cell Transplant: A Focus on Leading Causes of Morbidity and Mortality' is designated for a maximum of (or 'for up to') 1 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.


DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


FEE INFORMATION
There is no fee for this educational activity.


AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact RMEI Medical Education, LLC prior to the live event at (866) 770-RMEI.


SPONSOR STATEMENT
Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine.

Sponsor



Register Now

 

FOLLOW RMEI

Facebook Twitter


Additional educational activities offered by RMEI Medical Education, LLC can be found at www.RMEI.com or by calling toll-free (866) 770-RMEI.